Confronto
GHRP-6 vs. Tesamorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
87616-84-0
901758-09-6
Peso molecolare
873.02 g/mol
5135.83 g/mol
Emivita
0.4 h
0.4 h
Sequenza
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2Meccanismo d'azione
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Tesamorelin
Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
2
4
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between GHRP-6 and Tesamorelin?
- GHRP-6 is classified as "Crescita", while Tesamorelin is classified as "Crescita". GHRP-6: Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s as the first orally and parenterally active GH secretagogue with no structural similarity to GHRH. Never approved as a medicine; downstream analogs (GHRP-2, hexarelin, ipamorelin) were pursued clinically. Tesamorelin: Stabilised GHRH analog (growth-hormone-releasing hormone). FDA-approved in 2010 as Egrifta for reduction of abdominal lipohypertrophy in HIV-associated lipodystrophy. Not approved for the general population. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, GHRP-6 or Tesamorelin?
- The highest available evidence level is "Studio sull'uomo" for GHRP-6 and "RCT sull'uomo" for Tesamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of GHRP-6 and Tesamorelin in Germany and the United States?
- Germania: GHRP-6 — Non approvato, Tesamorelin — Non approvato. Stati Uniti: GHRP-6 — Non approvato, Tesamorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.